INTRODUCTION
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urine [4] , and roughly 16% of total serum concentrations are bound to plasma proteins [5] . Cefepime displays linear pharmacokinetics over a range of doses [4, 6] . In patients with normal renal function, cefepime has an elimination half-life of 2-3 hours in adults [4] , 1.5-1.9 hours in infants and children [6] , and 4.9 hours in neonates [7] . In patients with renal failure and in those receiving continuous renal replacement therapy, total body clearance is delayed [8, 9] , necessitating the use of longer dosing intervals or lower total daily doses.
Cefepime demonstrates time-dependent bactericidal activity in which its efficacy is defined by the fraction of time for which the free (unbound) concentration is maintained above the minimum inhibitory concentration (MIC) of the bacteria being treated. The classic pharmacodynamic (PD) target that is associated with improved clinical outcomes for cefepime has been maintenance of drug concentrations above the MIC (fT>MIC) for ≥60% of dosing interval [10] . However, more recent data have suggested that more aggressive PD targets, maintaining drug concentrations above the MIC for the entire dosing interval (100% fT>MIC), should be used to ensure optimal clinical and microbiological outcomes [11, 12] . Successful treatment of harder to treat infections, such as Gram-negative pneumonia, may require the administration of doses that maintain free serum concentrations at least 2-fold higher than the MIC for the entire dosing interval (100% fT>2xMIC, or fC min >2 xMIC) [13] . Meanwhile, in vitro studies have demonstrated that suppression of resistance selection during therapy occurs with an even more robust PD target of fC min >3.8xMIC [14] . These latter data are consistent with in vitro time-kill studies for Pseudomonas aeruginosa that show increased bacterial killing for β-lactam agents at concentrations up to 4 times the MIC [15] ; based on these time-kill data, some studies have used fT>4xMIC as the optimal PD target for β-lactam antibiotics [12] .
In 2014, the Clinical and Laboratory Standards Institute (CLSI) revised cefepime interpretive criteria (breakpoints) for the treatment of Enterobacteriaceae based on data showing clinical failures and low probability of target attainment using standard cefepime dosing in adults infected with Gram-negative bacteria with an MIC of 4 and 8 µg/mL [16, 17] . To optimize the administration of cefepime, CLSI employed the designation of "susceptible-dose dependent" (SDD) for isolates with an MIC of 4 and 8 µg/mL [17] . This change was made to signal that dosing regimens that result in higher drug exposures (i.e. higher doses or more frequent dosing) be administered to give the highest probability of adequate coverage of these isolates [17] . Instead of using the term "intermediate", which is often clinically interpreted as "resistant," the SDD designation was implemented to encourage the administration of cefepime at high doses rather than discourage its use for treatment of less susceptible isolates. The SDD designation does not apply to Pseudomonas aeruginosa and other non-Enterobacteriaceae Gram-negatives since the approved dosing regimen for treatment of these organisms differ [17] .
There is accumulating evidence in critically ill adults that standard β-lactam dosing by intermittent infusion, including for cefepime, often produces inadequate antibiotic concentrations contributing to suboptimal outcomes [12, [18] [19] . Pediatric studies also have found that traditional dosing via intermittent infusion may be inadequate for less susceptible Gram-negative pathogens [20] . As a result, there is increased acceptance that administration of ββ-lactam agents as an extended or continuous infusion maximizes the likelihood of PD target attainment in critically ill patients [21] . The administration of cefepime as a prolonged infusion significantly increases the probability of PD target attainment compared to intermittent infusion, even for isolates in the SDD range [20, 22] . A recent meta-analysis of 6 randomized controlled trials (RCTs) and 4 observational studies found that prolonged infusion of meropenem was associated with higher clinical success rate (odds ratio 2.10, 95% CI 1.31-3.38) and lower mortality (risk ratio 0.66, 95% CI 0.50-0.88) in adult patients with severe infections compared to intermittent infusion [23] . Similarly, in a meta-analysis of 13 RCTs comparing continuous infusion versus intermittent bolus of β-lactam agents in critically adult patients with respiratory infections, continuous infusion was associated with higher cure rates (risk ratio 1.18, 95% CI 1.07-1.30) [24] . Although data specific to cefepime are limited, there is mounting evidence that the use of prolonged infusions improves the likelihood of PD target attainment, which is especially important in patients with critical illness, serious bacterial infections, and infections caused by isolates with decreased susceptibility to the β-lactam agent being administered.
The production of β-lactamases is the most frequent and important mechanism of resistance to β-lactam antibiotics among Gram-negative bacteria. Extended-spectrum β-lactamases (ESBLs), carbapenemases, and AmpC β-lactamases have the capacity to hydrolyze drugs in this class with SHV-, OXA-and CTX-M-type enzymes being most prominent among Pseudomonas aeruginosa and Enterobacteraciae [25, 26] . CTX-M-15 is the most widely distributed CTX-M-type ESBL and isolates producing this enzyme have higher MICs to cefepime than other ESBLs [27] . As noted above, maintenance of drug concentrations 4-fold above the MIC for the entire dosing interval decreases selection of resistance during cefepime therapy in a hollow-fiber infection model [14] . Although in vivo studies are needed to validate this target, optimized antibiotic exposures can prevent, or at least delay, the development of resistance among Gram-negative bacteria during treatment, particularly in high-burden infections such as pneumonia or undrained, intra-abdominal abscesses.
While administration of large doses can facilitate achievement of higher drug concentrations, cefepime is associated with dose-dependent toxicity particularly neurotoxicity [28] [29] [30] [31] , especially in patients with renal dysfunction, limiting the administration of overly large doses. In a single-center retrospective study of adult patient receiving cefepime who underwent therapeutic drug monitoring (TDM), a neurologic event considered possibly related to cefepime occurred in 11% of 93 patients [29] ; patients with C min > 20 mg/L had a 5-fold higher risk for neurologic events (OR 5.1, 95% CI 1.3-19.8) and those with a C min > 40 mg/L had a 9-fold higher risk (OR 9.4, 95% CI 2.2-39.5). Decreased renal function was significantly associated with neurotoxicity [29] . Similarly, in a study of adult patients receiving cefepime for febrile neutropenia, high cefepime concentrations were an independent predictor of neurological toxicity with a 50% probability of toxicity at C min > 22mg/L [30] . Patients with acute or chronic renal dysfunction may have reduced clearance of cefepime, depending on the degree of glomerular filtration impairment, and are at increased risk of exposure-dependent neurotoxicity.
It is crucial to individualize cefepime dosing in order to achieve concentrations that optimize efficacy, limit selection of resistant bacteria, and avoid toxicity. This is especially true for critically ill patients and those with Gram-negative infections caused by less susceptible isolates who are at high risk of suboptimal drug exposures and resultant clinical failure, as well as patients with renal dysfunction at higher risk for cefepime-induced neurotoxicity. Monitoring of blood concentrations is particularly important in order to guide dosing that will achieve targeted serum drug concentrations. Although data demonstrating improved clinical outcomes with TDM for β-lactam agents are limited, TDM has been shown to improve PD target attainment in critically ill patients for various drugs in this class [32] [33] [34] . As a result, β-lactam TDM is becoming an increasingly valued part of clinical care of critically ill patients [21, [35] [36] .
In order to facilitate TDM, quantitative drug assays need to provide precise results with short turnaround time. For cefepime, drug concentrations are most often measured using validated high-performance liquid chromatography (HPLC) or liquid chromatography-tan-dem mass spectrometry (LC-MS/MS) methods [37] [38] [39] [40] . Cefepime poses an added challenge for TDM due to rapid ex-vivo degradation in plasma at room temperature, requiring that all processing occur at 4°C [39] . The purpose of this review is to list the various LC-MS/MS methods in human blood, plasma, and serum for quantitation of cefepime with information on sample preparation, chromatographic and mass spectrometric conditions and validation parameters ( Table 1 ) and to discuss relevant bioanalytical strategies and considerations for implementation of LC-MS/MS assays for therapeutic drug monitoring (TDM) of cefepime.
LC-MS/MS methods for cefepime analysis
Cefepime (Figure 1 Sample preparation Sample preparation is a critical step in bioanalytical method development. Due to limited stability of cefepime in plasma and serum at room temperature, samples should be immediately placed on ice after collection and processed at 4˚C temperature to provide accurate results. Plasma [41, 42] and serum [43] [44] [45] samples have been used as the biological matrix for cefepime TDM assays. Sample cleanup by removal of interfering matrix components (proteins, salts, and lipids) is often necessary to reduce the risk of matrix effects in LC-MS/MS procedures and to provide required selectivity, sensitivity, and ruggedness. The two most common methods for sample cleanup are (i) protein precipitation and (ii) solid-phase extraction (SPE) for cefepime TDM assays. For protein precipitation, the majority of the reported assays utilize methanol or acetonitrile as the precipitation and extraction solvents. SPE with Oasis HLB cartridges was utilized by Ohmori et al. [43] , and an online SPE cleanup with Oasis HLB column was employed by Zander et al. [45] . These assays utilized stable labeled 2 D 3 -cefepime or 13 C 2 D 3 -cefepime as an internal standard, which provides several advantages in the accurate quantitation of drug levels in biological samples such as faster run time, improvement in intra-injection reproducibility, reduction of matrix effects and better sensitivity.
Chromatography and detection
Reverse phase chromatography was utilized for reported methods to separate cefepime from other molecules in the biological sample extract by partitioning between the mobile and stationary phases. Ammonium formate buffer or water with 0.1% formic acid was used as the aqueous mobile phase and methanol or acetonitrile with 0.1% formic acid was used as organic mobile phase. Nonpolar or hydrocarbon-like systems (C8, C18, Phenyl and F5) were used as the stationary phases. The majority of reported LC-MS/ MS methods utilized tandem mass spectrometry for the detection and quantitation of cefepime, with the exception of Lefeuvre et al. [41] . Cefepime is an inner salt and readily ionizes in the positive mode to provide excellent response. Multiple reaction monitoring transitions used by various methods is summarized in Table 1 . The most common products of cefepime fragmentation that were utilized for quantitation were m/z 481.0 [M + H] + → m/z 167 and 86.1 [42] [43] [44] . In some cases, doubly charged ion of cefepime m/z 241 [M + 2H] 2+ was used to monitor the product m/z 227 for quantitation [41, 45] .
DISCUSSION
Recently published LC-MS/MS assays for cefepime TDM are summarized in Table 1 . Paal et al. [44] , reported a HPLC-MS/MS method for quantification of cefepime along with five other antibiotics in human serum ( Table 1) . The method employs a simple sample cleanup by protein precipitation and analysis utilizing stable labeled internal standards. Method utilized separation with C8 reverse phase HPLC column followed by MS/MS detection with clinically relevant concentration ranges. The assay demonstrated excellent selectivity, linearity and dilution integrity. Analytes were stable for 6 h at room temperature, 24 h at 4 °C, and two weeks at -20 °C.
Lefeuvre et al. [41] , reported an UHPLC-HRMS assay for the simultaneous quantitation of cefepime and 14 other antibiotics in human plasma ( Table 1) . Sample cleanup involved protein precipitation followed by separation with C18 reverse phase chromatography. High-resolution full scan data acquisition was utilized for detection. Cefepime was stable for 48 h at room temperature and 2 -8 °C and 20 days at -20 °C. This UHPLC-HRMS assay has the advantage of using acquired data for the retrospective analysis of metabolites.
Rigo-Bannin et al. [42] , developed and validated a UHPLC-MS/MS method for simultaneous quantitation of ten β-lactam antibiotics in human plasma ( Table 1) . Sample cleanup involved protein precipitation, dilution, C18 reverse phase chromatographic separation followed by tandem mass spectrometric detection. The method demonstrated good linearity, selectivity and robustness to be utilized for TDM analysis. Cefepime was stable for 3 days at room temperature and 5 ± 3 °C and 6 months at -75 ± 3 °C.
Zander et al. [45] , reported a UHPLC-MS/MS method for analysis of eight β-lactam antibiotics in human serum ( Table 1) . Sample cleanup involved SPE followed by C18 reverse phase chromatographic separation and tandem mass spectrometric detection. The assay demonstrated to be robust and successfully employed for the analysis of clinical samples.
Methods reported by Paal et al. [44] , and Rigo-Bannin et al. [42] , involved simple sample cleanup, robust chromatographic separation and tandem mass spectrometric detection. While other methods used complex sample preparation, 2D-HPLC or HRMS detection. Method by Paal et al. [44] is robust for analysis of cefepime in human serum with an efficient sample preparation and LC-MS/MS analysis. While method by Rigo-Bannin et al. [42] is robust for analysis of cefepime in human plasma with simple sample cleanup and UPLC-MS/MS analysis.
Cefepime has limited stability in human plasma and serum at room temperature and the duration of acceptable stability varies from 3 h to 3 days at room temperature based on different reports (Table 1) . However, the reason for these significant differences in the stability of cefepime in human plasma and serum at room temperature remains unresolved. It is critical to establish sufficient stability of cefepime during sample collection, storage, and processing to generate accurate quantitavie bioanalytical results.
Clinical Applications and Future Directions
In the current era of increasing antimicrobial resistance, it is paramount that antimicrobial dosing is personalized to assure optimal exposures that will result in clinical cure while minimizing the selection of resistant organisms. Therapeutic drug monitoring allows clinicians to provide individualized, target-oriented dosing for β-lactam antibiotics, including cefepime. Empiric dosing strategies, based on population PK modeling and Monte Carlo simulations, are designed to maximize the probability of target attainment. However, interand intra-variability in drug clearance and the volume of distribution prevents the use of a one-size-fits all dosing approach. The availability of LC-MS/MS assays that provide rapid and accurate measurement of cefepime concentrations can aid clinical pharmacists and clinicians in efforts to confirm drug exposures in individual patients, as well as facilitate adjustment of dosing in real-time to achieve desired levels. This is especially important in critically ill patients who require precise drug exposures to maximize bacterial killing and minimize the risk of toxicity. For instance, in a patient with a documented Gram-negative infection, clinicians can utilize TDM to estimate fT>MIC utilizing a variety of methods (i.e. Bayesian dose adaptation, log-linear regression, etc.). These data can then inform dose adjustments that aim to maximize the probability of target attainment in that patient. As described above, a number of PD targets have been associated with improved effectiveness outcomes, with >60% fT>MIC being the minimum time-dependent goal. TDM also holds potential to provide exposures that limit the selection of antimicrobial resistant phenotypes, although this has been predominantly established in vitro [14] . TDM in infants and children is challenged by a desire to minimize blood sampling, restrict entry into vascular access devices (i.e. central venous catheters), and avoid painful procedures such as venipuncture. Microsampling techniques can improve the performance of pediatric PK studies [46] [47] [48] , applying less invasive approaches to blood sampling and reducing the risks to the patient. The availability of validated cefepime assays that utilize as little as 50 µL of plasma or serum can facilitate the clinical application of microsampling techniques and promote TDM in patients where sampling is challenging. Furthermore, application of whole blood microsampling (10-20 µL) to quantify cefepime levels in pediatric patints will be a convenient and efficient approach for TDM. Recently, Barco et al. [49] , developed and validated a volumetric absorptive microsampling (VAMS™) assay for four antibiotics in human whole blood. VAMS™ approach allowed for accurate quantitation of drugs with no significant influence of hematocrit values. However, to employ VAMS™ approach for clinical studies, optimal collection, drying, shipping, and storage conditions with minimal drug degradation needs to be established. In addition, utility of VAMS™ approaches for TDM require converting whole blood concentrations to plasma or serum concentrations, where previously established reference ranges are available.
Further studies comparing VAMS™, venous blood, and plasma samples are required to assess any potential difference between capillary blood from finger pricks and venous blood. 
